The Role of SATB1 in Tumour Progression and Metastasis.
EMT
SATB1
Special AT-Rich Binding Protein 1
cancer
epidermal-mesenchymal transition
metastasis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Aug 2019
25 Aug 2019
Historique:
received:
02
07
2019
revised:
16
08
2019
accepted:
23
08
2019
entrez:
28
8
2019
pubmed:
28
8
2019
medline:
23
1
2020
Statut:
epublish
Résumé
Carcinogenesis is a long-drawn, multistep process, in which metastatic spread is an unequivocal hallmark of a poor prognosis. The progression and dissemination of epithelial cancers is commonly thought to rely on the epidermal-mesenchymal transition (EMT) process. During EMT, epithelial cells lose their junctions and apical-basal polarity, and they acquire a mesenchymal phenotype with its migratory and invasive capabilities. One of the proteins involved in cancer progression and EMT may be SATB1 (Special AT-Rich Binding Protein 1)-a chromatin organiser and a global transcriptional regulator. SATB1 organizes chromatin into spatial loops, providing a "docking site" necessary for the binding of further transcription factors and chromatin modifying enzymes. SATB1 has the ability to regulate whole sets of genes, even those located on distant chromosomes. SATB1 was found to be overexpressed in numerous malignancies, including lymphomas, breast, colorectal, prostate, liver, bladder and ovarian cancers. In the solid tumours, an elevated SATB1 level was observed to be associated with an aggressive phenotype, presence of lymph node, distant metastases, and a poor prognosis. In this review, we briefly describe the prognostic significance of SATB1 expression in most common human cancers, and analyse its impact on EMT and metastasis.
Identifiants
pubmed: 31450715
pii: ijms20174156
doi: 10.3390/ijms20174156
pmc: PMC6747166
pii:
doi:
Substances chimiques
Matrix Attachment Region Binding Proteins
0
SATB1 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Hum Vaccin Immunother. 2017 Aug 3;13(8):1741-1750
pubmed: 28575585
Oncol Lett. 2017 Sep;14(3):3611-3615
pubmed: 28927120
Genes Dev. 2009 Nov 15;23(22):2625-38
pubmed: 19933152
J Clin Invest. 2009 Jul;119(7):1763-71
pubmed: 19587451
Cancer Genomics Proteomics. 2016 May-Jun;13(3):209-17
pubmed: 27107063
Mol Cell Biochem. 2013 Jun;378(1-2):39-45
pubmed: 23516037
APMIS. 2010 Nov;118(11):855-63
pubmed: 20955458
Oncotarget. 2018 Jun 12;9(45):27708-27727
pubmed: 29963231
Cancer Biol Ther. 2016;17(3):254-61
pubmed: 26810818
Mol Med Rep. 2015 May;11(5):3235-542
pubmed: 25586771
Methods. 2012 Nov;58(3):243-54
pubmed: 22782115
J Ovarian Res. 2012 Sep 19;5(1):24
pubmed: 22992394
J Cancer Res Clin Oncol. 2017 May;143(5):745-757
pubmed: 27686824
Genes Dev. 2000 Mar 1;14(5):521-35
pubmed: 10716941
Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2256-64
pubmed: 27338049
PLoS One. 2013;8(1):e53527
pubmed: 23308245
Histopathology. 2014 Aug;65(2):155-63
pubmed: 24118100
Histol Histopathol. 2007 May;22(5):483-95
pubmed: 17330803
In Vivo. 2018 Jul-Aug;32(4):731-736
pubmed: 29936452
Anticancer Res. 2016 Aug;36(8):4069-76
pubmed: 27466515
Int J Cancer. 2011 Jun 1;128(11):2527-35
pubmed: 21365651
Exp Ther Med. 2015 May;9(5):1665-1669
pubmed: 26136875
Int J Colorectal Dis. 2012 Feb;27(2):143-50
pubmed: 21870058
Oncol Rep. 2010 Oct;24(4):981-7
pubmed: 20811679
BMC Cancer. 2018 Oct 1;18(1):939
pubmed: 30285678
Trends Cancer. 2016 Feb;2(2):65-67
pubmed: 27042694
Carcinogenesis. 2013 Aug;34(8):1889-99
pubmed: 23542418
Dis Esophagus. 2016 Aug;29(6):621-6
pubmed: 25951709
Oncotarget. 2016 Jan 26;7(4):4993-5006
pubmed: 26701851
Oncol Lett. 2017 Dec;14(6):6592-6596
pubmed: 29151908
Nature. 2002 Jan 31;415(6871):530-6
pubmed: 11823860
Tumour Biol. 2013 Oct;34(5):2497-506
pubmed: 23873099
Cell Death Differ. 2011 Jan;18(1):16-25
pubmed: 20798686
Int J Cancer. 2014 Dec 1;135(11):2537-46
pubmed: 24729451
Mol Cell Biol. 2009 Mar;29(5):1321-37
pubmed: 19103759
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6152-7
pubmed: 19369214
Carcinogenesis. 2011 Sep;32(9):1299-304
pubmed: 21665887
BMC Med Genomics. 2014 Dec 11;7:68
pubmed: 25496125
Cancer Cell Int. 2013 Feb 05;13(1):8
pubmed: 23379909
Genet Mol Res. 2015 Apr 13;14(2):3309-17
pubmed: 25966097
Front Physiol. 2018 May 15;9:535
pubmed: 29867574
NPJ Syst Biol Appl. 2018 Aug 23;4:34
pubmed: 30155271
Nature. 2008 Mar 13;452(7184):187-93
pubmed: 18337816
J Cell Sci. 2007 Jun 15;120(Pt 12):2053-65
pubmed: 17550972
Diagn Pathol. 2012 Aug 30;7:115
pubmed: 22935204
Curr Opin Genet Dev. 2007 Oct;17(5):408-14
pubmed: 17913490
Diagn Pathol. 2015 May 09;10:50
pubmed: 25956130
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23
pubmed: 25535351
Immunol Cell Biol. 2019 May;97(5):498-511
pubmed: 30803026
Br J Cancer. 1954 Mar;8(1):1-12
pubmed: 13172380
Cell. 1992 Aug 21;70(4):631-45
pubmed: 1505028
Oncotarget. 2015 Dec 1;6(38):41134-45
pubmed: 26512778
Oncol Rep. 2013 May;29(5):1811-8
pubmed: 23483190
Med Hypotheses. 2011 Feb;76(2):277-9
pubmed: 21122998
J Transl Med. 2013 May 04;11:111
pubmed: 23642278
Semin Cancer Biol. 2013 Apr;23(2):72-9
pubmed: 22771615
Tumour Biol. 2016 Jan;37(1):185-97
pubmed: 26602382
J Transl Med. 2014 Oct 17;12:289
pubmed: 25323550
J Natl Cancer Inst. 2010 Dec 15;102(24):1879-80; author reply 1880-1
pubmed: 21076049
Mol Med Rep. 2017 Dec;16(6):8842-8848
pubmed: 28990092
Oncol Lett. 2016 Nov;12(5):3818-3824
pubmed: 27895736
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
PLoS One. 2014 Mar 27;9(3):e92924
pubmed: 24675979
Dig Dis Sci. 2015 Nov;60(11):3304-17
pubmed: 26108419
Cancer Cell Int. 2009 Jul 30;9:18
pubmed: 19642980
Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
pubmed: 17318226
Mol Cell. 2006 Apr 21;22(2):231-43
pubmed: 16630892
Br J Cancer. 1953 Mar;7(1):68-72
pubmed: 13051507
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Mol Cancer. 2017 Dec 02;16(1):176
pubmed: 29197379
Mol Med Rep. 2010 Sep-Oct;3(5):857-61
pubmed: 21472326
Oncotarget. 2017 Mar 14;8(11):17771-17784
pubmed: 28147311
Clin Transl Oncol. 2016 Sep;18(9):878-83
pubmed: 26563145
PLoS One. 2013;8(2):e56730
pubmed: 23437226
Folia Histochem Cytobiol. 2013;51(4):333-8
pubmed: 24497139
PLoS One. 2013;8(1):e47902
pubmed: 23326301
Cancer Res. 2005 Apr 15;65(8):3063-71
pubmed: 15833835
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Breast. 2011 Aug;20(4):309-13
pubmed: 20980149
Oncol Lett. 2017 Apr;13(4):2577-2582
pubmed: 28454436
Oncol Lett. 2012 Apr 1;3(4):865-870
pubmed: 22741008
Nat Med. 2002 Aug;8(8):816-24
pubmed: 12118244
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Anticancer Res. 2018 Feb;38(2):723-736
pubmed: 29374696
Chin J Cancer Res. 2018 Jun;30(3):291-298
pubmed: 30046223
Int J Gynecol Cancer. 2015 Jan;25(1):4-11
pubmed: 25347096
Cell Death Dis. 2018 Feb 21;9(3):303
pubmed: 29467441
Oncogene. 2016 Mar 31;35(13):1679-91
pubmed: 26165840
Prog Mol Biol Transl Sci. 2013;116:263-89
pubmed: 23481199
J Transl Med. 2012 Jul 28;10:149
pubmed: 22839214
Prog Mol Biol Transl Sci. 2013;116:317-36
pubmed: 23481201
Tumour Biol. 2015 Jun;36(6):4441-52
pubmed: 25874491
Biochim Biophys Acta. 2013 Dec;1833(12):2653-2663
pubmed: 23830916
Liver Int. 2012 Aug;32(7):1064-78
pubmed: 22583549
Jpn J Clin Oncol. 2015 Sep;45(9):812-8
pubmed: 26117495
Nan Fang Yi Ke Da Xue Xue Bao. 2012 Jun;32(7):986-90, 994
pubmed: 22820583
Exp Ther Med. 2018 May;15(5):4339-4343
pubmed: 29725375
Curr Opin Cell Biol. 2016 Dec;43:7-13
pubmed: 27371787
Cell Physiol Biochem. 2016;38(5):1975-83
pubmed: 27161300
Onco Targets Ther. 2018 Oct 11;11:6811-6825
pubmed: 30349314
Virchows Arch. 2014 Dec;465(6):649-59
pubmed: 25326863
Mol Biol Cell. 2008 Nov;19(11):4875-87
pubmed: 18799618
Cancer Biol Ther. 2015;16(12):1738-45
pubmed: 26528635
Biomed Pharmacother. 2016 Apr;79:1-8
pubmed: 27044805
J Cell Commun Signal. 2016 Sep;10(3):223-227
pubmed: 27613407
APMIS. 2015 Feb;123(2):93-101
pubmed: 25257341
Curr Cancer Drug Targets. 2013 Nov;13(9):963-972
pubmed: 24168186
PLoS One. 2014 Jun 27;9(6):e100413
pubmed: 24971456
Oncotarget. 2017 Jul 18;8(29):48410-48423
pubmed: 28430598
Oncol Rep. 2012 Dec;28(6):2029-34
pubmed: 22972305
J Cell Biol. 2011 Sep 19;194(6):825-39
pubmed: 21930775
Cancer Manag Res. 2018 Jun 08;10:1471-1478
pubmed: 29922091
PLoS One. 2015 Feb 23;10(2):e0117518
pubmed: 25706386
Tumour Biol. 2013 Oct;34(5):2943-9
pubmed: 23696028
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Tumour Biol. 2015 Nov;36(11):9073-81
pubmed: 26084613
Oncogene. 2012 Feb 23;31(8):1045-54
pubmed: 21743493
Drug Des Devel Ther. 2016 Apr 18;10:1419-41
pubmed: 27143851
Nan Fang Yi Ke Da Xue Xue Bao. 2009 Mar;29(3):534-7
pubmed: 19304547
J Thorac Oncol. 2011 Jul;6(7):1179-89
pubmed: 21597389
Cell. 2006 Nov 17;127(4):679-95
pubmed: 17110329
Am J Pathol. 2005 Dec;167(6):1763-75
pubmed: 16314486
Urol Oncol. 2018 Mar;36(3):93.e13-93.e21
pubmed: 29079132
J Natl Cancer Inst. 2010 Aug 18;102(16):1284-96
pubmed: 20595686